Study of a blood protein level in autoimmune disease
Part of Immune system & allergy clinical trials.
This study looks at how a specific protein on cell surfaces (called STIM1) appears in people with autoimmune diseases. The goal is to understand what affects this protein and how it may relate to autoimmune illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with an autoimmune disease
- You have not taken rituximab within the past 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
This study looks at blood and immune cell markers (autoantibodies and immune cell “signatures”) to better understand autoimmune conditions, including lupus. It may help researchers identify which markers are linked to disease and how immune cells respond after vaccination.
This study measures blood “biomarkers” (signals in blood) to better understand inflammatory diseases, including autoimmune and autoinflammatory conditions. You may be asked to give blood samples now and possibly extra samples if needed for testing.
This study looks at immune cells in people with certain autoimmune diseases or immune deficiencies. The goal is to understand how these cells work, which may help improve future treatments.
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
This study is looking for people about to start immune checkpoint inhibitor therapy to see if certain antibodies are present. It may help understand how the body reacts to this treatment.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.